Syndax Pharmaceuticals Hits New 52-Week High

Shares of the biotech company reach new milestone, but should investors buy?

Apr. 8, 2026 at 2:10pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic biotech machinery and components, conveying the complex, high-tech nature of Syndax Pharmaceuticals' cancer research and drug development.Syndax Pharmaceuticals' new 52-week stock price high signals growing investor confidence in the biotech company's pipeline of cancer treatments.Waltham Today

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) saw its stock price hit a new 52-week high of $25.70 on Wednesday, up from a previous close of $24.64. The biotech company, headquartered in Waltham, Massachusetts, has seen its shares rise steadily in recent months as it advances its pipeline of cancer treatments.

Why it matters

Syndax's stock performance is a positive sign for the company, which has been working to develop novel therapies for cancer treatment. The new 52-week high suggests growing investor confidence in the company's prospects, though analysts remain divided on whether the current valuation presents a buying opportunity.

The details

Syndax's lead investigational candidate is entinostat, a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. The company has reported positive data from clinical trials of entinostat in combination with other cancer treatments, driving investor interest.

  • Syndax Pharmaceuticals stock hit a new 52-week high of $25.70 on Wednesday, April 8, 2026.
  • The stock had previously closed at $24.64 on the same day.

The players

Syndax Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company dedicated to developing novel cancer therapies, headquartered in Waltham, Massachusetts.

Got photos? Submit your photos here. ›

The takeaway

Syndax Pharmaceuticals' new 52-week high reflects growing investor confidence in the company's pipeline of cancer treatments, particularly its lead candidate entinostat. However, analysts remain divided on whether the current valuation presents a buying opportunity, underscoring the need for further data and regulatory milestones to solidify the company's long-term prospects.